VACCINOGEN
Vaccinogen manufactures vaccines and other immunotherapeutic products for cancers and infectious diseases. It operates as a biotechnology company that develops OncoVAX, an Active Specific Immunotherapy (ASI) vaccine which uses the patient's own cancer cells to block the return of colon cancer following surgery. The company was incorporated in 2007 and is based in Frederick, Maryland.
VACCINOGEN
Industry:
Biotechnology Health Care Therapeutics
Founded:
2007-01-01
Address:
Frederick, Maryland, United States
Country:
United States
Website Url:
http://www.vaccinogeninc.com
Total Employee:
11+
Status:
Active
Contact:
301-668-8400
Email Addresses:
[email protected]
Total Funding:
99.05 M USD
Technology used in webpage:
BuyVM
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
FruitVaccine
FruitVaccine manufactures fruit-based vaccines to provide immunity against globally problematic infectious diseases.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Juvaris BioTherapeutics
Juvaris BioTherapeutics develops adjuvanted vaccines and immunotherapeutics to treat cancer and infectious diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.vaccinogeninc.com
- Host name: 172.67.192.157
- IP address: 172.67.192.157
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vaccinogen"
Vaccinogen - Crunchbase Company Profile & Funding
Vaccinogen manufactures vaccines and other immunotherapeutic products for cancers and infectious diseases. It operates as a biotechnology company that develops OncoVAX, an …See details»
Vaccinogen - Wikipedia
Vaccinogen Inc. is a US biotechnology company based in Baltimore. It is currently developing a potential cancer immunotherapy called OncoVAX, where a patient's own tumor cells are used as the vaccine, adjuvanted by BCG. This product was evaluated in Phase III in colon cancer in the 1990s and another Phase III study, called ACTIVE, is currently recruiting stage II colon cancer patients. Vaccinogen calls its approach 'Active Specific Immunotherapy' or ASI. See details»
Vaccinogen Company Profile 2024: Valuation, Funding …
Vaccinogen Inc is a biotechnology company focused on the development and commercialization of cancer vaccines and immunotherapeutic products for cancers. Its primary product is OncoVAX, an autologous cancer vaccine …See details»
Vaccinogen Company Profile - Craft
Vaccinogen is a biotechnology company specializing in personalized vaccines using a patient's immune system to fight cancer. It provides OncoVAX, an autologous cancer vaccine …See details»
Vaccinogen, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Vaccinogen, Inc. of Baltimore, MD. Get the latest business insights from Dun & Bradstreet.See details»
Vaccinogen - LinkedIn
Vaccinogen is a US-based biotechnology company formed in 2007 to complete the pivotal trial of a new vaccine for Stage II Colon Cancer, OncoVAX.See details»
Vaccinogen - Wikiwand articles
Vaccinogen Inc. is a US biotechnology company based in Baltimore. It is currently developing a potential cancer immunotherapy called OncoVAX, where a patient's own tumor cells are used …See details»
Vaccinogen Relocates Corporate Headquarters to Baltimore - PR …
BALTIMORE, Feb. 24, 2015 /PRNewswire/ -- Vaccinogen (OTC.QB: VGEN), a leading cancer immunotherapy company, announced that it has relocated its corporate headquarters from …See details»
Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as …
May 5, 2015 · Vaccinogen, Inc. is a cancer vaccine company that is clinically testing OncoVAX®, a treatment designed to prevent the recurrence of colon cancer and potentially other solid …See details»
Vaccinogen, Inc. (Vaccinogen, Inc.) - 药物管线_专利_临床试验_投融 …
了解Vaccinogen, Inc. (Vaccinogen, Inc.)公司的药物管线，治疗领域，技术平台，以及它的1项临床试和4篇文献，药物:Autologous cancer vaccine (Vaccinogen)。See details»
Research programme: human monoclonal antibodies - Vaccinogen
Vaccinogen is developing human monoclonal antibodies from the patients previously immunised using Vaccinogen's OncoVAX®[see RDI profile 800011670]. TheSee details»
Vaccinogen Closes Second Tranche of $80 Million Financing at …
Jan 28, 2015 · These filings can also be found on Vaccinogen's web site at www.vaccinogeninc.com. Vaccinogen, Inc. is a cancer vaccine company that is clinically …See details»
Vaccinogen Believes That Its "Whole-Tumor Methodology" and …
Dec 2, 2015 · Vaccinogen believes that these findings support its whole-tumor methodology and its OncoVAX® immunotherapy platform which was originally designed to address the extreme …See details»
Vaccinogen Lands $80M - VC News Daily
Vaccinogen, Inc., a cancer immunotherapy development company, announced today that it completed the initial closing of a private placement of $80 million of units and common stock. …See details»
Safety and efficacy of autologous tumour cell vaccines as a cancer ...
We aim to review evidence from controlled and uncontrolled interventional studies of autologous cell vaccines administered to patients with cancer to determine their historical efficacy (with or …See details»
Vaccinogen - Company Profile - Tracxn
Oct 20, 2024 · Vaccinogen - Autologous cancer vaccine for the post-surgical treatment of Stage II colon cancer.. Public Company. Raised a total funding of $16.6M over 7 rounds from 1 …See details»
Vaccinogen Completes Initial Closing of an $80 Million Financing
Aug 25, 2014 · Vaccinogen, Inc. is a cancer vaccine company that is clinically testing its OncoVAX® treatment which is designed to prevent the recurrence of colon cancer and …See details»
Vaccines and immunization - World Health Organization (WHO)
Nov 18, 2024 · Vaccines reduce risks of getting a disease by working with your body’s natural defenses to build protection. When you get a vaccine, your immune system responds. We now …See details»
Vaccinogen Names Dr. Peter Morsing as Head of Business …
FREDERICK, Md., Jan. 12, 2015 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a leader in cancer immunotherapy development, announced today that Peter Morsing, Ph.D., a 20-year …See details»
Vaccinogen Enhances Patient-Derived Antibody Program with …
Sep 9, 2015 · Vaccinogen, Inc. is a cancer vaccine company clinically testing OncoVAX ®, a treatment designed to prevent the recurrence of colon cancer and potentially other solid …See details»